Evogene Ltd. (NYSE:EVGN) Q2 2020 Earnings Conference Call - Final Transcript
Aug 05, 2020 • 09:00 am ET
second quarter of 2019. Although the Company decreased its cash burn rate during the quarter, we experienced an increase in general and administrative expenses, mostly attributed to an increase in the cost of the Company's D&O insurance.
Operating loss for the second quarter of 2020 was $5.2 million, including a non-cash expense of $0.9 million for amortization of share-based compensation, mainly attributed to options granted to Lavie Bio employees in comparison to $4.7 million, including non-cash expenses of $0.2 million for amortization of share-based compensation, in the second quarter of 2019. The loss for the second quarter of 2020 was $4.8 million in comparison to loss of $4.1 million during the second quarter of 2019.
With that said, we would now like to open up the call for any questions you may have. Operator?